BioClinica Signs Enterprise Agreement for Electronic Data Capture

BioClinica Signs Enterprise Agreement for Electronic Data Capture
- Multi-Year Deal With Top 10 Company is Second Full Service EDC Win of 2010 -
 

NEWTOWN, Pa., Oct 07, 2010 (BUSINESS WIRE) -- BioClinica(TM), Inc., /quotes/comstock/15*!bioc/quotes/nls/bioc (BIOC 3.65, -0.03, -0.82%) , a leading provider of clinical trial management services, today announced that it has signed a three-year, multi-million dollar agreement for enterprise-wide EDC technology and data management services with a global, multi-billion dollar division of a Top 10 pharmaceutical company. Designed for maximum efficiency and flexibility, BioClinica Express(TM) will support nearly 200 studies annually for this organization. Together the firms have developed a common data model based on CDISC standards that will facilitate rapid deployment and study closeout while supporting a challenging clinical environment.

The client chose BioClinica Express as part of a broad evaluation of all the leading solutions to achieve its goal of running paperless clinic studies. This agreement marks the second enterprise-level, full-service EDC agreement that BioClinica has announced this year. BioClinica announced a similar agreement for BioClinica Express and data management services with Cephalon in February.

"Our client analyzed a wide variety of commercial EDC vendor options, including open source software. They selected BioClinica for its technology, clinical domain expertise and its experience in handling high volumes of clinical data study builds and deployments," said Stephen Boccardo, VP of Sales.

BioClinica Express is a comprehensive EDC solution that coordinates and organizes the collection and dissemination of clean data, adding speed and quality to every part of the clinical trial process. Express will be used for direct data entry and BioClinica's full service data management staff will assure that all data is cleaned and processed in a timely manner.

"This client is already recognized as a worldwide leader in therapeutic research -- now they are blazing new paths in efficiency and speed. BioClinica will help this organization to implement standards that will deliver efficiency and eliminate variability, which are the true keys to success. Through our partnership, BioClinica will help to support their challenging clinical environment where many studies are designed and deployed within a single week," said Peter Benton, President of the eClinical Division for BioClinica.

"We believe this selection demonstrates the value that BioClinica's unique strategy brings to clinical research, especially at the company-wide level. We are proud to offer this best-in-class solution to support our clients as they continue to pioneer scientific research on a global scale," said Mark Weinstein, CEO of BioClinica.

Follow BioClinica on the Trial Blazers blog at http://info.bioclinica.com/blog, and on twitter at http://twitter.com/bioclinica.

About BioClinica, Inc.

BioClinica, Inc. is a leading global provider of integrated, technology-enhanced clinical trial management services. BioClinica supports pharmaceutical and medical device innovation with imaging core lab, internet image transport, electronic data capture, interactive voice and web response, Microsoft Office-Smart clinical trial management and clinical supply chain design and optimization solutions. BioClinica services maximize efficiency and manageability throughout all phases of the clinical trial process. With more than 20 years of experience and over 2,000 successful trials to date, BioClinica has supported the clinical development of many new medicines from early phase trials through final approval. BioClinica operates state-of-the-art, regulatory-body-compliant imaging core labs on two continents, and supports worldwide eClinical and data management services from offices in the United States, Europe and Asia. For more information, please visit www.bioclinica.com.

Suggested Articles

Eli Lilly is combining the oncology team at Lilly Research Laboratories with Loxo Oncology and putting a trio of Loxo execs at the helm.

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.

The data tee Aurinia up to file for FDA approval next year and go on to address a major unmet medical need.